Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2025

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

Presenter: Hyun-Jong Lee

October 28, 2025

Presentation TCT 2025

TCT 59: Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

Presenter: Jinying Zhou

October 28, 2025

Presentation TCT 2025

TCT 159: Effect of Evolocumab on coronary segments with calcified nodules: Insights from the YELLOW III study

Presenter: Pruthvi C. Revaiah

October 26, 2025

Presentation TCT 2025

Effect of EVOlocumab on Infarct Size in Patients with STEMI: The Prospective, Randomized, Open-Label EVO-STEMI Study

Presenter: Hyun-Jong Lee

October 25, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

Presentation TCT 2023

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Presenter: Prakriti Gaba

October 26, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

Presentation ESC 2022

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Presenter: Michelle L. O’Donoghue

August 29, 2022

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Advertisement

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

TCT 59: Evolocumab in Patients with Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation

TCT 159: Effect of Evolocumab on coronary segments with calcified nodules: Insights from the YELLOW III study

Effect of EVOlocumab on Infarct Size in Patients with STEMI: The Prospective, Randomized, Open-Label EVO-STEMI Study

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

TCT 423: Long-term Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition with Evolocumab and Aortic Stenosis Events – An Analysis from FOURIER and FOURIER-OLE

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content